Symbolic image of waning vaccine protection over time.

Meningitis C Immunity: Are We Protected Enough?

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 4 min read.

"A Dutch study reveals the long-term impact of the MenC vaccine and raises questions about waning immunity."


Meningitis C is a serious infection that can lead to severe complications, especially in young children and adolescents. In 2002, the Netherlands introduced the Meningococcal C conjugate vaccine (MenCC) as a single dose for children at 14 months, followed by a catch-up campaign for those up to 18 years old. This initiative dramatically reduced MenC cases, but what about long-term protection?

A recent study investigated MenC-specific immunity in the Dutch population before and after the introduction of the MenCC vaccine. By analyzing serum samples collected in 1995/1996 and 2006/2007, researchers aimed to understand how the vaccine has impacted immunity levels over time.

This article breaks down the key findings of this research, exploring the effectiveness of the MenCC vaccine, how immunity changes with age, and what these insights might mean for future vaccination strategies and the ongoing protection of our communities.

AI Search Multiple angles on this topic

Current Vaccination Approach

CDC's current meningococcal vaccine recommendations are organized by age, risk, and vaccine type. CDC recommends meningococcal vaccination for all adolescents and for children and adults at increased risk of meningococcal disease. A 2020 systematic literature review examined the immediate and long-term impact and effectiveness of different monovalent meningococcal C conjugate vaccine schedules and strategies used in routine immunization programs. The WHO International Standard for Meningococcal Serogroup C supports laboratory quantification of MenC vaccine content across several assay methods.

From Polysaccharides to Conjugates

Meningococcal vaccine development progressed alongside innovation in vaccines for other diseases. This history produced polysaccharide vaccines against meningococci with group A, C, W, and Y capsules, followed by polysaccharide conjugate vaccines. A later review identifies conjugate vaccines and reverse vaccinology as novel approaches that led to successful vaccines and a favorable global impact on invasive meningococcal disease. Earlier meningococcal polysaccharide vaccines were used primarily during outbreaks because their protection was short-term and they were ineffective in children under two.

How Effective is the MenC Vaccine Over Time?

Symbolic image of waning vaccine protection over time.

The study revealed some interesting trends in MenC-specific immunity. In individuals who received the catch-up immunization, MenC PS-specific IgG (a type of antibody) increased gradually with age, suggesting a sustained immune response in those vaccinated at older ages. However, for those vaccinated before the age of 5, these antibodies seemed to decline more rapidly.

The research also looked at serum bactericidal antibodies (SBA), which indicate functional immunity. Overall, SBA seroprevalence (the proportion of people with protective antibody levels) increased significantly after the MenC vaccine introduction. But what does this mean for different age groups?

  • Adolescents and Adults: The MenCC vaccine led to improved protection in adolescents.
  • Infants: A single-dose schedule may not provide sufficient long-term protection, potentially requiring a booster dose in adolescence.
  • Non-immunized Adults: PS-specific IgG was significantly lower after the MenC vaccination era, indicating that natural exposure to Meningitis C decreased.
AI Search Multiple angles on this topic

Duration and Immune Memory

Recent research is examining vaccine effectiveness and the duration of protection after primary and booster immunization with MenC and MenACWY conjugate vaccines. A 2024 study specifically set out to estimate vaccine effectiveness against MenC invasive meningococcal disease and compare the duration of protection following these immunization strategies. Research on ageing populations also reports that historical circulation of meningococci W and Y in the Netherlands has been very low, suggesting that vaccination may induce naive-type responses in older adults. Current clinical discussions additionally include updates on invasive meningococcal disease, pentavalent vaccines, policy shifts, and provider guidance.

Protection Can Wane

Evidence from the Dutch population indicates that a large-scale MenC conjugate vaccination program improved protection in adolescents, but a single infant dose may not provide sufficient long-term protection. The same research suggests that a booster dose in early adolescence should be considered because increasing numbers of children who received only primary immunization at 14 months may become less well protected. The systematic review of MenC conjugate vaccines examined both long-term effectiveness and vaccine failures, including failures reported during 2015-2016. CDC describes the Vaccine Adverse Event Reporting System as an early-warning system for potential vaccine safety problems rather than as proof that every reported event was caused by vaccination.

Conjugate Vaccines and Protection

A study summarized in the PLOS source reported that residual bactericidal antibody titers of at least 8 remained in only 37% of children two years after immunization at around two years of age. Broader evidence indicates that meningococcal conjugate C, ACWY, and outer-membrane-vesicle vaccines are effective at reducing invasive meningococcal disease. The same review found that a small number of studies showed monovalent C conjugate vaccines could reduce pharyngeal Neisseria meningitidis carriage. These findings distinguish protection against invasive disease from the more limited evidence concerning carriage reduction.

These findings highlight the complex dynamics of vaccine-induced immunity and the importance of monitoring protection levels across different age groups.

What Does This Mean for the Future of Meningitis C Prevention?

The Dutch study provides valuable insights into the long-term impact of the MenCC vaccine. While the vaccine has been highly effective in reducing MenC cases, the findings suggest that a single-dose schedule in infancy may not provide sufficient long-term protection. This raises questions about the potential need for booster doses, particularly as those initially vaccinated as infants enter adolescence.

AI Search Multiple angles on this topic

Recommendations Vary by Country

Meningococcal vaccination recommendations for people at increased risk of invasive meningococcal disease differ across countries. For example, MenACWY and MenB vaccines are recommended for people with HIV infection in Ireland, New Zealand, and Australia, while France recommends MenC vaccination only for this group. Italy recommends an unspecified anti-meningococcal vaccine in the cited comparison. The review's expert opinion is that recommendations should be standardized to cover all groups at increased risk of invasive meningococcal disease.

Toward a World Free of Meningitis

The WHO roadmap described in a 2026 Nature perspective envisions a world free of meningitis. Its goals include eliminating meningitis epidemics, reducing vaccine-preventable cases, and reducing disability. Current global discussions also focus on epidemiological trends in invasive meningococcal disease after the COVID-19 pandemic and disease prevalence in at-risk populations. The same discussions highlight research into pentavalent meningococcal vaccines containing MenACWY conjugates.

Measuring Vaccine Impact

Invasive meningococcal disease has a low and unpredictable incidence, which makes real-world evaluation of meningococcal vaccines challenging. Traditional evaluations have therefore assessed vaccine impact by predicting counterfactual outcomes from the period before immunization. A 2020 systematic review aimed to characterize MenC conjugate vaccine failures and estimate effectiveness from 2005-2016, including during the 2015-2016 outbreak. These methodological challenges mean that assessing protection requires more than simply comparing observed case counts.

Population-Level Effects

A Brazilian ecological population-based study assessed the impact of meningococcal C conjugate vaccine on invasive meningococcal disease and MenC across the North, Northeast, Midwest, South, and Southeast regions. It used interrupted time-series analysis and national data from 2001 through 2019. A separate review concluded that both polysaccharide and conjugate vaccines have demonstrated impact and effectiveness against vaccine-serogroup meningococcal disease. Together, these sources connect vaccination policy with population-level changes in disease occurrence.

Furthermore, the lower IgG levels observed in non-immunized adults in the post-vaccination era warrant careful monitoring. If MenC circulation were to increase, these individuals might be at increased risk.

Ultimately, ongoing surveillance and adaptive vaccination strategies are crucial to ensure continued protection against Meningitis C and to safeguard public health.

What Dutch serum surveys can establish

Observational study (level 4 of 8)

Two cross-sectional, population-based serum banks let researchers compare antibody measurements across Dutch population samples before and after vaccine introduction; they do not track the same individuals over time or establish individual protection from disease.[1]

Vaccination dates were available for most people in cohorts eligible for the vaccine, so comparisons by immunization history were possible but not complete for that group.[2]

Where antibody evidence has limits

  • They note that antibody levels in women of childbearing age were also low, which could leave newborns with limited maternal antibody cover.[2]
  • The authors caution that SBA results in some infants were not attributable to MenC polysaccharide antibodies alone.[2]

The Dutch population study at a glance

Study designObservational study[1]
Sample size8539 in 1995/1996 and 6386 in 2006/2007[1]
SettingThe Netherlands[1]
ComparisonPre-MenC introduction era versus post-MenC introduction era[1]
Main outcomeMenC polysaccharide-specific IgG levels and serum bactericidal antibody levels[1]
Effect sizeSBA seroprevalence increased from 19.7% to 43.0% in the pre- and post-introduction eras[1]
Times cited80[1]

What a follow-up would need to resolve

  • Would antibody measurements in the same people over time show how quickly protection changes after infant vaccination compared with later immunization?[3]
  • How closely do measured IgG and SBA levels correspond to actual disease protection when circulation and natural boosting are low?[1] [3]
  • Would reduced MenC circulation affect antibody persistence differently in vaccinated people and those without recorded immunization?[1]

Sources

  1. Immunity against Neisseria meningitidis Serogroup C in the Dutch Population before and after Introduction of the Meningococcal C Conjugate Vaccine (Public Library of Science (PLoS), 2010)
  2. Immunity against Neisseria meningitidis Serogroup C in the Dutch Population before and after Introduction of the Meningococcal C Conjugate Vaccine (Europe PMC, 2010)
  3. Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1371/journal.pone.0012144, Alternate LINK

Title: Immunity Against Neisseria Meningitidis Serogroup C In The Dutch Population Before And After Introduction Of The Meningococcal C Conjugate Vaccine

Subject: Multidisciplinary

Journal: PLoS ONE

Publisher: Public Library of Science (PLoS)

Authors: Richarda M. De Voer, Liesbeth Mollema, Rutger M. Schepp, Sabine C. De Greeff, Pieter G. M. Van Gageldonk, Hester E. De Melker, Elisabeth A. M. Sanders, Guy A. M. Berbers, Fiona R. M. Van Der Klis

Published: 2010-08-13

Everything You Need To Know

1

What is the Meningococcal C conjugate vaccine (MenCC), and what was its purpose?

The Meningococcal C conjugate vaccine (MenCC) is a vaccine introduced in the Netherlands in 2002 to combat Meningitis C, a serious infection. It was initially administered as a single dose to children at 14 months, followed by a catch-up campaign for those up to 18 years old. The primary goal of the MenCC vaccine was to reduce the number of Meningitis C cases, and it proved highly effective in achieving this, significantly decreasing the incidence of the disease. It is significant because it changed how the population was protected against Meningitis C.

2

What specific measures were used to assess the impact of the MenCC vaccine on immunity?

The study examined two key indicators of immunity: MenC PS-specific IgG antibodies and serum bactericidal antibodies (SBA). MenC PS-specific IgG levels, a type of antibody, were measured to understand the immune response over time. The research also evaluated SBA seroprevalence, which indicates the presence of functional immunity capable of neutralizing the bacteria. These measurements were crucial to assess the vaccine's effectiveness and how immunity varied across different age groups, providing insights into the long-term protection provided by the MenCC vaccine.

3

What are the potential implications of these findings for future vaccination strategies?

The Dutch study's findings have implications for future vaccination strategies. For infants, a single dose might not offer long-term immunity, possibly necessitating booster doses during adolescence. The study showed that the MenCC vaccine led to improved protection in adolescents. The decline in Meningitis C exposure among non-immunized adults is also relevant, showing a shift in the population's immune landscape. These insights suggest the importance of continuous monitoring of immunity levels and could influence future decisions on vaccination schedules to maintain community protection.

4

How has the MenCC vaccine affected the overall effectiveness and immunity levels?

The MenCC vaccine has been effective in reducing Meningitis C cases. After the vaccine introduction, there was a noticeable increase in the proportion of people with protective antibody levels (SBA seroprevalence). However, the study showed that immunity levels varied depending on the age at which the vaccine was received. While those who received the catch-up immunization showed sustained immune response, those vaccinated before age 5 had a more rapid decline in antibodies. This highlights the need to consider age-specific approaches for optimal protection.

5

What are the key takeaways about the long-term effectiveness of the MenCC vaccine?

The study revealed that the MenCC vaccine's effectiveness and long-term protection is complex. While it was highly effective in reducing Meningitis C cases, a single dose given in infancy might not provide sufficient long-term protection. This raises the question of whether booster doses are needed, especially as those initially vaccinated as infants grow older. This is particularly important because natural exposure to Meningitis C decreased after the MenCC vaccination program. The findings emphasize the need for continued monitoring of immunity and potentially adjusting vaccination strategies to ensure sustained protection across different age groups.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.